MedTrace Logo

A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma

NCT02914938 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 97

Last updated 2023-05-09

No results posted yet for this study

Summary

A Three-Arm Study of ME-401 in Subjects with Relapsed/Refractory CLL/SLL or FL, of ME-401 in Combination with Rituximab in Subjects with Relapsed/Refractory CLL/SLL or B-cell NHL, and of ME-401 in Combination with Zanubrutinib in Subjects with Relapsed/Refractory CLL/SLL or B-cell NHL

Conditions

  • Chronic Lymphocytic Leukemia (CLL)
  • Small Lymphocytic Lymphoma (SLL)
  • Follicular Lymphoma (FL)
  • Marginal Zone B Cell Lymphoma
  • Diffuse Large B-cell Lymphoma (DLBCL)
  • High Grade Non-Hodgkin's Lymphoma
  • Mantle Cell Lymphoma (MCL)

Interventions

DRUG

ME-401

60 mg

DRUG

Rituximab

IV infusion 375 mg/m2

DRUG

Zanubrutinib

80 and 160 mg bid

Sponsors & Collaborators

  • MEI Pharma, Inc.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-10-31
Primary Completion
2023-03-29
Completion
2023-03-29

Countries

  • United States
  • Switzerland

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02914938 on ClinicalTrials.gov